Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.